A

Adaptimmune Therapeutics plc
D

ADAP

0.56000
USD
-0.02
(-3.11%)
مغلق
حجم التداول
6,331
الربح لكل سهم
-0
العائد الربحي
-
P/E
-3
حجم السوق
143,294,596
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار
المقالات

العنوان: Adaptimmune Therapeutics plc

القطاع: Healthcare
الصناعة: Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.